DEVELOPMENT OF MULTI-ANTIGEN MRNA VACCINE AGAINST FELINE FIPV

PAN-SARBECOVIRUS NANOPARTICLE VACCINES

TREATMENT USING A ONE-TO-STOP ATTENUATED SARS-COV-2 VIRUS

COMBINATION CONTAINING AN MRNA VACCINE OR AN MRNA ENCODED THERAPEUTIC PROTEIN AND AN IMMUNE MODULATING MRNA FOR IMPROVED OR REDUCED IMMUNOGENICITY TO INCREASE EFFICACY

IMMUNIZATION METHOD AGAINST INFECTION BY SARS-CoV-2

PHARMACEUTICAL COMPOSITION FOR RESISTING INFECTION WITH SARS-COV-2 OR MUTANT THEREOF, AND COMBINED DRUG THEREOF

CORONAVIRUS VACCINE, PRODUCTION AND APPLICATION

VACCINE COMPOSITION FOR SUBLINGUAL ADMINISTRATION

SARS-COV-2 VACCINE BOOSTER COMPOSITION

SELF-REPLICATING RNA VACCINES AND METHODS OF USE

RECOMBINANT VACCINE AGAINST COVID-19 TO PRODUCE CELLULAR RESPONSE IN INDIVIDUALS WITH PRE-EXISTING IMMUNITY

THERAPEUTIC INTERFERING PARTICLES FOR CORONA VIRUS

COMPOSITIONS AND METHODS FOR INCREASING VIRAL NUCLEOCAPSID PROTEIN DIMERIZATION

SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES

CORONAVIRUS VACCINES

NOVEL PEPTIDE CONJUGATE VACCINES

ONE-TO-STOP ATTENUATED SARS-COV-2 VIRUS

SURFACE CONJUGATION TO POLY(AMINE-CO-ESTER) NANOPARTICLES FOR TARGETING TO CELLS AND TISSUES

POXVIRUS-BASED VECTORS PRODUCED BY NATURAL OR SYNTHETIC DNA AND USES THEREOF

Engineered Probiotic Delivery System for Anti-SARS-COV-2 Treatment and Immunity Against Viruses

INTERFERON-PRODUCING UNIVERSAL SARBECOVIRUS VACCINES, AND USES THEREOF

NOVEL REOVIRUS-BASED VACCINE PLATFORM AND USE THEREOF

TETANUS VACCINE PLATFORM FOR EMBEDDING COVID-19 VACCINE

COMPOSITIONS AND METHODS FOR FcRn-TARGETED INTRANASAL CORONAVIRUS VACCINATION

FUSION POLYPEPTIDE

SELF-AMPLIFYING RNA COMPOSITIONS AND METHODS OF USE THEREOF

SARS-COV-2 S PROTEIN POLYPEPTIDE ANTIGEN AND APPLICATION THEREOF

PORCINE CORONAVIRUS VACCINES

RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING SPIKE PROTEIN OF SARS-COV-2 DELTA VARIANT AND USES THEREOF

CHIMERIC BETACORONAVIRUS SPIKE POLYPEPTIDES

VACCINES FOR IN VIVO EXPRESSION OF NUCLEIC ACIDS AND METHODS OF USING THE SAME

METHODS OF PREVENTING, TREATING, OR REDUCING THE SEVERITY OF COVID-19 IN IMMUNOCOMPROMISED BLOOD CANCER PATIENTS

APPLICATION OF NOVEL CORONAVIRUS VACCINE PEPTIDE AND NANOEMULSION PREPARATION THEREOF IN PREVENTION OF NOVEL CORONAVIRUS WILD AND MUTANT STRAINS

ANTIGEN DELIVERY PLATFORM AND METHODS OF USE

MRNA VACCINE DESIGN VIA THE ALTERATION OF CODON USAGE

IMMUNOGENIC FUSION PROTEINS AGAINST CORONAVIRUS

A VACCINE FOR CORONAVIRUS AND INFLUENZA VIRUS, AND METHOD FOR PREPARATION THEREOF

CORONAVIRUS VACCINE

Cationic Lipid Compound and Composition for Delivery of Nucleic Acids and Use Thereof

A DNA PLASMID SARS-CORONA VIRUS-2/COVID-19 VACCINE

RECOMBINANT MEASLES VIRUS

COVID-19 VACCINES WITH TOCOPHEROL-CONTAINING SQUALENE EMULSION ADJUVANTS

Peptide VLP-Based Vaccines

POLYPEPTIDE FRAGMENTS, IMMUNOGENIC COMPOSITION AGAINST SARS-CoV-2, AND IMPLEMENTATIONS THEREOF

COMPOSITIONS AND METHODS FOR MUCOSAL VACCINATION AGAINST SARS-COV-2

Vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus

IMMUNOGENIC COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST VARIANTS OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)

RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING SARS-COV-2 SPIKE PROTEIN AND ITS USE

MODIFIED VIRUS-LIKE PARTICLES OF BACTERIOPHAGE AP205

EXTENDED-RANGE SPRAY APPLICATOR

VACCINE COMPOSITION COMPRISING A LEISHMANIA HOST CELL EXPRESSING AT LEAST ONE PROTEIN OF THE FAMILY CORONAVIRIDAE

METHOD FOR INDUCING CELLULAR IMMUNITY TO INFECTION BY SARS-CoV-2

Interferon-producing universal sarbecovirus vaccines, and uses thereof

Vaccines and Antibodies for the Treatment and Prevention of Microbial Infections

REVERSE GENETICS-BASED COMPOSITIONS OF RECOMBINANT SARS-COV-2

VACCINE FORMULATION COMPRISING RECOMBINANT OVERLAPPING PEPTIDES AND NATIVE PROTEINS

Coronavirus vaccine

Coronavirus vaccine

RECOMBINANT VECTORS ENCODING CHIMERIC CORONAVIRUS SPIKE PROTEINS AND USE THEREOF

TEMPERATURE-SENSITIVE BETACORONAVIRUS STRAIN AND VACCINE

SAR-COV-2 DNA Vaccine and Method of Administering Thereof

IMMUNOGENIC COMPOSITIONS AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2

Coronavirus vaccine

SINGLE-CHAIN CORONAVIRUS VIRAL MEMBRANE PROTEIN COMPLEXES

Peptides and Combinations of Peptides for Use in Immunotherapy Against an Infection by Sars-COV-2 (COVID-19)

REAGENTS AND METHODS FOR PREVENTING, TREATING OR LIMITING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) CORONAVIRUS INFECTION

AAV5-BASED VACCINE AGAINST SARS-COV-2

VARIANT SARS-CoV-2 PROTEINS AND USES THEREOF

CELLULAR VACCINE PLATFORM AND METHODS OF USE

CORONAVIRUS VACCINE

ENGINEERING CORONAVIRUS SPIKE PROTEINS AS VACCINE ANTIGENS, THEIR DESIGN AND USES

RAPID VACCINE PLATFORM

SARS-CoV-2 Vaccines and Antibodies

PREPARATION METHOD AND APPLICATION OF INTERFERING PEPTIDE TARGETING SARS-CoV-2 N PROTEIN

ENGINEERING BROADLY REACTIVE CORONAVIRUS VACCINES AND RELATED DESIGNS AND USES

Coronavirus Disease 2019(COVID -19) Recombinant Spike Protein Forming Trimer, Method for Mass Producing Recombinant Spike Protein in Plants, and Method for Preparing Vaccine Composition on Basis Thereof

VACCINE COMPOSITIONS COMPRISING ENDOGENOUS GAG POLYPEPTIDES

Tetanus vaccine platform for embedding COVID-19 vaccine

IMMUNOGENIC COMPOSITIONS AND USES THEREOF

CORONAVIRUS VACCINE COMPOSITIONS AND METHODS OF USE

COMPOSITIONS AND METHODS FOR DETECTING AND TREATING A SARS-COV-2 INFECTION

RECOMBINANT BACTERIA FOR USE AS A VACCINE TO PREVENT COVID19 INFECTION

RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION, AND METHODS OF USING THE SAME FOR TREATING COVID-19

Use of Human Resistin as a Trimerization Partner for Expression of Trimeric Proteins

PERSISTENT MEMORY T-CELL RESPONSES TO CANCER AND INFECTIOUS-DISEASE ANTIGENS BY MANIPULATION OF AMINO ACID-CATABOLISM PATHWAYS

MERS-CoV VACCINE

ANTIGEN SPECIFIC EPITOPE BASED ANTI-INFECTIVE VACCINES

DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF

CORONAVIRUS VACCINES COMPRISING A TLR9 AGONIST

POXVIRUS-BASED VECTORS PRODUCED BY NATURAL OR SYNTHETIC DNA AND USES THEREOF

Coronavirus vaccine compositions, methods, and uses thereof

CORONAVIRUS VACCINES AND METHODS OF USE

Synthetic pDNA vaccines against COVID-19

Peptides for the treatment of COVID-19

MODIFIED SPIKE PROTEIN AND METHOD OF TREATMENT

Method of treating or preventing clinical signs caused by infectious bronchitis virus with 4/91 IBV vaccine having heterologous spike protein

RECOMBINANT ADENOVIRUS VACCINE FOR CORONA VIRUS DISEASE 19 AND COMBINATION THERAPY USING THE SAME

AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LIQUID FORM (VARIANTS)

Neutralizing antibody immunoassays

IMMUNOMODULATION PLATFORM AND METHODS OF USE

EXPRESSION VECTOR AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2

PHARMACEUTICAL COMPOSITION CONTAINING STABILIZED NUCLEIC ACID ADJUVANT

Hybrid alphavirus-SARS-CoV-2 particle and methodology of making and using same

Recombinant polypeptides containing at least one immunogenic fragment and antibody fc region and uses thereof

Composition and method of mRNA vaccines against novel coronavirus infection

Prime-boost vaccination regimen

Coronavirus vaccine compositions, methods, and uses thereof

Viral vaccines for in vivo expression of a nucleic acid encoding an immunogenic peptide and methods of using the same

Compositions and methods for preventing and treating coronavirus infection—SARS-CoV-2 vaccines

Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Prefusion coronavirus spike proteins and their use

Compositions and methods for preventing and treating coronavirus infection—SARS-CoV-2 vaccines

Extended-range spray applicator

Antigen-surface-coupled liposome vaccine for non-human animals

Live attenuated Arkansas serotype infectious bronchitis virus vaccine

Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly

Antigen-binding molecule capable of binding two or more antigen molecules repeatedly

NSP10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications

H52 IBV vaccine with heterologous spike protein

4/91 IBV vaccine with heterologous spike protein

Expression of PEDV sequences in plants and plant produced vaccine for same

Prefusion coronavirus spike proteins and their use

ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY

Porcine coronavirus vaccines

Immunogenic composition for MERS coronavirus infection

LIVE ATTENUATED ARKANSAS SEROTYPE INFECTIOUS BRONCHITIS VIRUS VACCINE

Vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus

Attenuated infectious bronchitis virus

NSP10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications

ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TWO OR MORE ANTIGEN MOLECULES REPEATEDLY

Antigen-binding molecule capable of binding two or more antigen molecules repeatedly

Live attenuated Arkansas serotype infectious bronchitis virus vaccine

Whole expressed cell as antigen carrier, and use thereof in preparing vaccine or diagnostic agent, and screening monoclonal antibodies

IBV strains and uses thereof

Adaptation of attenuated infectious bronchitis virus (IBV) to embryonic kidney cells and vaccine thereby produced

Immunogenicity of an optimized synthetic consensus DNA vaccine for porcine epidemic diarrhea virus

Vaccine for Use in Protecting Offspring of a Sow Against Porcine Endemic Diarrhea Virus

LPS vaccine

Attenuated bovine coronavirus and related vaccines

Vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus

IBV strains and uses thereof

Coronavirus proteins and antigens

Gene-deleted variant strain of porcine pseudorabies virus, vaccine composition, method of making the same and use thereof

Gene-deleted variant strain of porcine pseudorabies virus, vaccine composition, method of making the same and use thereof

Immunogenic middle east respiratory syndrome coronavirus (MERS-CoV) compositions and methods

Adaptation of attenuated infectious bronchitis virus (IBV) to embryonic kidney cells and vaccine thereby produced

Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly

Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly

Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly

ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY

Nucleic acid-based adjuvant and porcine vaccine composition including the same